Equity · Healthcare
MIRM
NASDAQMirum Pharmaceuticals (MIRM)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 7.7B USD
- Revenue, year to Dec 2025
- 521.3M USD
- EPS, diluted, year to Dec 2025
- −0.47 USD
- 52-week range
- 51 USD – 128 USD
- Avg volume
- 193.8K
as of Jul 17, 2026
Have Mirum Pharmaceuticals (MIRM) insiders bought or sold shares recently?
In the 90 days to 15 Nov 2026, Mirum Pharmaceuticals insiders reported 6 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 23 Jan 2026.
Form 4, 90 days to 15 Nov 2026, newest reported trade 11 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 11 Nov 2026 | Brege LauraDirector | Sell | 14,167 | 1.3M USD |
| 04 Nov 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER | Sell | 20,000 | 1.8M USD |
| 14 Sep 2026 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER | Sell | 9,943 | 978K USD |
| 02 Sep 2026 | Howe JolandaSVP, GLOBAL CONTROLLER | Sell | 658 | 66K USD |
| 01 Sep 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER | Sell | 30,000 | 3.0M USD |
| 18 Aug 2026 | Howe JolandaSVP, GLOBAL CONTROLLER | Sell | 40,000 | 4.0M USD |
| Sold | 6 open-market sales | 114,768 | $11.14M |
7 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 11 Nov 2026 | Brege LauraDirector | Option exercise | 14,167 | 237K USD |
| 04 Nov 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER | Option exercise | 20,000 | 59K USD |
| 16 Oct 2026 | Howe JolandaSVP, GLOBAL CONTROLLER | Option exercise | 16,112 | 310K USD |
| 06 Oct 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER | Option exercise | 12,197 | 211K USD |
| 11 Sep 2026 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER | Option exercise | 18,333 | |
| 01 Sep 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER | Option exercise | 30,000 | 88K USD |
| 18 Aug 2026 | Howe JolandaSVP, GLOBAL CONTROLLER | Option exercise | 40,000 | 251K USD |
Which funds hold Mirum Pharmaceuticals (MIRM)?
2 of the 45 institutional funds we track reported a Mirum Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 47.7M USD; the latest of those filings landed 12 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Held (±25%) | 361,385 | 30.9M USD | −18.3% |
| Fisher Asset Management | Added | 196,199 | 16.8M USD | +137.9% |
What has been filed or recorded for Mirum Pharmaceuticals (MIRM)?
The filings we hold for Mirum Pharmaceuticals, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 2 shares | 163 USD notional · <0.001% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 748 shares | 60K USD notional · 0.001% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 116 shares | 9K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 26,924 shares | 2.4M USD notional · 0.041% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.87 USD | |
| 30 Sep 2026 | Financials | Total assets | 1.0B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | −54.2M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.06 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −13.43 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.47 USD | |
| 31 Dec 2025 | Financials | Revenue | 521.3M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −23.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.47 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.05 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.12 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.30 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.85 USD |
What do people ask about Mirum Pharmaceuticals (MIRM)?
What is Mirum Pharmaceuticals’ market cap?7.7B
Mirum Pharmaceuticals is worth 7.7B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is Mirum Pharmaceuticals’ revenue?521.3M
Mirum Pharmaceuticals reported revenue of 521.3M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Mirum Pharmaceuticals insiders bought or sold shares recently?6 sales
In the 90 days to 15 Nov 2026, Mirum Pharmaceuticals insiders reported 6 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 23 Jan 2026. A further 7 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Mirum Pharmaceuticals?2 of 45
2 of the 45 funds we track reported a Mirum Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies and Fisher Asset Management. See Funds
When did Mirum Pharmaceuticals last report earnings?−0.87
Mirum Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.87 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings